Sponsored Links
| Pharmasset Announces The Continued Enrollment Of The Phase 2b Clinical Trial Of RG7128 For The Treatment Of Hepatitis C |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Pharmasset, Inc. (Nasdaq: VRUS) announced that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection... Read more: Liver Disease / Hepatitis News From Medical News Today
|